| Year |
Citation |
Score |
| 2020 |
Ram RR, Duatschek P, Margot N, Abram M, Geleziunas R, Hesselgesser J, Callebaut C. Activation of HIV-specific CD8+ T-cells from HIV+ donors by vesatolimod. Antiviral Therapy. 25: 163-169. PMID 32420906 DOI: 10.3851/Imp3359 |
0.467 |
|
| 2020 |
Margot N, Ram R, Abram M, Haubrich R, Callebaut C. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V. Antimicrobial Agents and Chemotherapy. 64. PMID 31988104 DOI: 10.1128/Aac.02557-19 |
0.594 |
|
| 2019 |
Margot NA, Ram RR, White KL, Abram ME, Callebaut C. Antiviral Activity of HIV-1 Integrase Strand Transfer Inhibitors against Mutants with Integrase Resistance-Associated Mutations and their Frequency in Treatment-Naïve Individuals. Journal of Medical Virology. PMID 31389026 DOI: 10.1002/Jmv.25564 |
0.496 |
|
| 2017 |
Margot NA, Wong P, Kulkarni R, White K, Porter D, Abram ME, Callebaut C, Miller MD. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. The Journal of Infectious Diseases. 215: 920-927. PMID 28453836 DOI: 10.1093/Infdis/Jix015 |
0.486 |
|
| 2017 |
Margot NA, Wong P, Kulkarni R, White K, Porter D, Abram ME, Callebaut C, Miller MD. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse Transcriptase and Protease in Antiretroviral Treatment-Naïve Patients do not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimens. The Journal of Infectious Diseases. PMID 28329343 DOI: 10.1093/infdis/jix015 |
0.408 |
|
| 2017 |
Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial(). Hiv Clinical Trials. 1-6. PMID 28303753 DOI: 10.1080/15284336.2017.1291867 |
0.41 |
|
| 2017 |
Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J, Stein DK, Bellos N, Scarsella A, Yan M, Abram ME, Cheng A, Rhee MS. Long-term (96-week) Efficacy and Safety After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in HIV-infected, Virologically Suppressed Adults. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 28272164 DOI: 10.1097/Qai.0000000000001344 |
0.492 |
|
| 2017 |
Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, Miller MD. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. Plos One. 12: e0172206. PMID 28212411 DOI: 10.1371/Journal.Pone.0172206 |
0.5 |
|
| 2016 |
Post FA, Tebas P, Clarke A, Cotte L, Short W, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 27673443 DOI: 10.1097/Qai.0000000000001186 |
0.483 |
|
| 2016 |
Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. The Lancet. Hiv. 3: e158-65. PMID 27036991 DOI: 10.1016/S2352-3018(16)00024-2 |
0.398 |
|
| 2015 |
Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 26627107 DOI: 10.1097/Qai.0000000000000908 |
0.403 |
|
| 2015 |
Gallant JE, Koenig E, Andrade-Villanueva JF, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Rizzardini G, Fehr J, Liu HC, Abram ME, Cao H, Szwarcberg J. Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. Journal of Acquired Immune Deficiency Syndromes (1999). 69: 338-40. PMID 26181707 DOI: 10.1097/Qai.0000000000000598 |
0.351 |
|
| 2015 |
Andreatta K, Kulkarni R, Abram ME, Nguyen T, Cao H, Miller MD, White KL. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen. Journal of Acquired Immune Deficiency Syndromes (1999). 68: 519-26. PMID 25559592 DOI: 10.1097/Qai.0000000000000503 |
0.526 |
|
| 2015 |
Post FA, Winston J, Andrade-Villanueva JF, Fisher M, Liu Y, Beraud C, Abram ME, Graham H, Rhee MS, Cheng AK, Szwarcberg J. Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment. Journal of Acquired Immune Deficiency Syndromes (1999). 68: 310-3. PMID 25469527 DOI: 10.1097/Qai.0000000000000476 |
0.396 |
|
| 2015 |
Abram ME, Tsiang M, White KL, Callebaut C, Miller MD. A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 59: 838-48. PMID 25403670 DOI: 10.1128/Aac.04163-14 |
0.46 |
|
| 2014 |
McDonald CK, Martorell C, Ramgopal M, Laplante F, Fisher M, Post FA, Liu Y, Curley J, Abram ME, Custodio J, Graham H, Rhee MS, Szwarcberg J. Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment. Hiv Clinical Trials. 15: 269-73. PMID 25433666 DOI: 10.1310/Hct1506-269 |
0.441 |
|
| 2014 |
Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients. Hiv Clinical Trials. 15: 218-30. PMID 25350960 DOI: 10.1310/Hct1504-218 |
0.521 |
|
| 2014 |
Abram ME, Ferris AL, Das K, Quinoñes O, Shao W, Tuske S, Alvord WG, Arnold E, Hughes SH. Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication. Journal of Virology. 88: 7589-601. PMID 24760888 DOI: 10.1128/Jvi.00302-14 |
0.542 |
|
| 2013 |
Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrobial Agents and Chemotherapy. 57: 2654-63. PMID 23529738 DOI: 10.1128/Aac.02568-12 |
0.532 |
|
| 2013 |
Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Plummer A, Abram M, Cheng AK, Fordyce MW, Szwarcberg J. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. Journal of Acquired Immune Deficiency Syndromes (1999). 62: 483-6. PMID 23337366 DOI: 10.1097/Qai.0B013E318286415C |
0.458 |
|
| 2010 |
Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. Journal of Virology. 84: 9864-78. PMID 20660205 DOI: 10.1128/Jvi.00915-10 |
0.542 |
|
| 2010 |
Abram ME, Sarafianos SG, Parniak MA. The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site. Retrovirology. 7: 6. PMID 20122159 DOI: 10.1186/1742-4690-7-6 |
0.626 |
|
| 2005 |
Abram ME, Parniak MA. Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. Journal of Virology. 79: 11952-61. PMID 16140771 DOI: 10.1128/Jvi.79.18.11952-11961.2005 |
0.651 |
|
| 2004 |
Sluis-Cremer N, Arion D, Abram ME, Parniak MA. Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. The International Journal of Biochemistry & Cell Biology. 36: 1836-47. PMID 15183348 DOI: 10.1016/J.Biocel.2004.02.020 |
0.626 |
|
| 2002 |
Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. The Journal of Biological Chemistry. 277: 1370-4. PMID 11684697 DOI: 10.1074/jbc.M110254200 |
0.599 |
|
| Show low-probability matches. |